Novartis Ag Revenue Growth Rates (NVS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Novartis Ag  (NYSE: NVS)
 

NVS's Revenue Growth by Quarter and Year

Novartis Ag's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVS Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 56,674.00
3rd Quarter September 0.00
2nd Quarter June 14,051.00
1st Quarter March 0.00
FY 70,725.00

NVSs Annual Revenue
Novartis Ag's Revenue in the fiscal year 2025 $ 56,674.00 millions
Novartis Ag's Revenue in the fiscal year 2024 $ 51,722.00 millions
Novartis Ag's Revenue in the fiscal year 2023 $ 46,660.00 millions
Novartis Ag's Revenue in the fiscal year 2022 $ 51,828.00 millions
Novartis Ag's Revenue in the fiscal year 2021 $ 52,877.00 millions




NVS Revenue fourth quarter 2024 Y/Y Growth Comment
Novartis Ag achieved in the fourth quarter 2024, above Company average Revenue improvement of 9.57% year on year, to $ 56,674.00 millions.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue growth. While Novartis Ag' s Revenue increase of 9.57% ranks overall at the positon no. 1470 in the fourth quarter 2024.


NVS Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 9.57 % 10.85 % -9.97 % -1.98 %
3rd Quarter September - - - -
2nd Quarter June 12.32 % 9.4 % -10.53 % -
1st Quarter March - - - -
FY   10.11 % 10.56 % -10.08 % -

Financial Statements
Novartis Ag's fourth quarter 2024 Revenue $ 56,674.00 millions NVS's Income Statement
Novartis Ag's fourth quarter 2023 Revenue $ 51,722.00 millions Quarterly NVS's Income Statement


NVS Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   10.11 % 10.56 % -10.08 % -


Back to NVS Growth rate Comparisons >> Back to NVS Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #263
Overall #1470

Revenue Y/Y Growth Statistics
High Average Low
10.85 % 1.21 % -9.97 %
(Dec 31 2021)   (Dec 31 2023)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #263
Overall #1470
Revenue Y/Y Growth Statistics
High Average Low
10.85 % 1.21 % -9.97 %
(Dec 31 2021)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Novartis Ag's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NVS's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NVS's IV. Quarter Q/Q Revenue Comment


Novartis Ag's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 56,674.00 $ 51,722.00 $ 46,660.00 $ 51,828.00 $ 52,877.00
Y / Y Revenue Growth (TTM) 9.57 % 10.85 % -9.97 % -1.98 % 5.97 %
Year on Year Revenue Growth Overall Ranking # 1568 # 0 # 1694 # 0 # 0
Seqeuential Revenue Change (TTM) 9.57 % 10.85 % -9.97 % -1.98 % 5.97 %
Seq. Revenue Growth (TTM) Overall Ranking # 1568 # 0 # 1694 # 0 # 0


Cumulative Revenue growth Comment
Assuming the Novartis Ag's fiscal year would have ended in Dec 31 2025, Novartis Ag would have reprted above average annual Revenue improvement of 9.57% year on year, of $ 56,674 millions.
This marks a slow-down of the companys growth trends and from the 10.85% rise in Dec 31 2024.

In the Healthcare sector 281 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1568.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 109
Healthcare Sector # 282
Overall # 1568

Revenue TTM Y/Y Growth Statistics
High Average Low
5.97 %
 -2.38 %
-9.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 109
Sector # 282
S&P 500 # 1568
Cumulative Revenue growth Comment
Assuming the Novartis Ag's fiscal year would have ended in Dec 31 2025, Novartis Ag would have reprted above average annual Revenue improvement of 9.57% year on year, of $ 56,674 millions.
This marks a slow-down of the companys growth trends and from the 10.85% rise in Dec 31 2024.

In the Healthcare sector 281 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1568.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 109
Healthcare Sector # 282
Overall # 1568

Revenue TTM Y/Y Growth Statistics
High Average Low
5.97 %
-2.38 %
-9.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 109
Sector # 282
S&P 500 # 1568




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NVS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Fortress Biotech Inc 16.38%$ 16.376 millions
Orthopediatrics Corp15.95%$ 15.945 millions
Concentra Group Holdings Parent Inc 15.92%$ 15.921 millions
Boston Scientific Corporation15.90%$ 15.896 millions
Electromed Inc 15.77%$ 15.774 millions
Evolus Inc 15.64%$ 15.636 millions
Lemaitre Vascular Inc 15.20%$ 15.197 millions
Envista Holdings Corporation15.01%$ 15.011 millions
Radnet Inc 14.80%$ 14.800 millions
Innovage Holding Corp 14.69%$ 14.693 millions
Kamada Ltd 14.54%$ 14.544 millions
Idexx Laboratories Inc14.40%$ 14.398 millions
Cerus Corporation14.33%$ 14.331 millions
Grail Inc 13.97%$ 13.973 millions
Dr Reddy s Laboratories Limited13.76%$ 13.761 millions
Pacific Biosciences Of California Inc 13.75%$ 13.750 millions
Dexcom Inc 13.19%$ 13.189 millions
Atricure Inc 13.05%$ 13.054 millions
Collegium Pharmaceutical Inc 12.92%$ 12.916 millions
Inspire Medical Systems inc 12.58%$ 12.577 millions
Qhslab Inc 12.43%$ 12.433 millions
Pacs Group Inc 12.43%$ 12.426 millions
U S Physical Therapy Inc12.35%$ 12.347 millions
Elanco Animal Health Incorporated12.16%$ 12.157 millions
Livanova Plc11.62%$ 11.618 millions
Amneal Pharmaceuticals Inc 11.59%$ 11.591 millions
Karyopharm Therapeutics Inc 11.58%$ 11.581 millions
Escalon Medical Corp 11.51%$ 11.515 millions
Stryker Corp11.42%$ 11.420 millions
Warby Parker Inc 11.41%$ 11.409 millions


About Novartis Ag Revenue Growth Rates (NVS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Novartis Ag (CIK 1114448).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001114448-26-000004
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Novartis Ag’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.